MA50979B1 - Application de totarol et composition pharmaceutique contenant du totarol - Google Patents
Application de totarol et composition pharmaceutique contenant du totarolInfo
- Publication number
- MA50979B1 MA50979B1 MA50979A MA50979A MA50979B1 MA 50979 B1 MA50979 B1 MA 50979B1 MA 50979 A MA50979 A MA 50979A MA 50979 A MA50979 A MA 50979A MA 50979 B1 MA50979 B1 MA 50979B1
- Authority
- MA
- Morocco
- Prior art keywords
- totarol
- treatment
- weight
- parts
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'invention concerne l'application de totarol pour la production d'une préparation pour le traitement d'inflammations de la membrane muqueuse vaginale d'origine bactérienne, pour le soulagement de symptômes dans un tel traitement et pour la prophylaxie et la prévention de récidives de telles inflammations. L'invention concerne également une composition pharmaceutique pour le traitement d'inflammations de la membrane muqueuse vaginale d'origine bactérienne, pour le soulagement de symptômes dans un tel traitement et pour la prophylaxie et la prévention de récidives de telles inflammations, la composition contenant de 75 à 95 parties en poids d'un dérivé de cellulose, de 0,5 à 5 parties en poids d'acide lactique, de 0,5 à 5 parties en poids d'un polymère basique, le rapport stœchiométrique entre l'acide lactique et le polymère basique étant compris dans la plage de 1:1 à 8:1 et comprenant du totarol en une quantité de 0,001 à 5 parties en poids en tant que principe actif.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL422140A PL236429B1 (pl) | 2017-07-06 | 2017-07-06 | Zastosowanie totarolu do wytwarzania preparatu do leczenia bakteryjnego zakażenia pochwy i kompozycja farmaceutyczna do zastosowania w leczeniu stanów zapalnych pochwy o podłożu bakteryjnym |
PCT/PL2018/000066 WO2019009739A1 (fr) | 2017-07-06 | 2018-07-04 | Application de totarol et composition pharmaceutique contenant du totarol |
Publications (2)
Publication Number | Publication Date |
---|---|
MA50979A MA50979A (fr) | 2020-10-14 |
MA50979B1 true MA50979B1 (fr) | 2022-11-30 |
Family
ID=63518002
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA050980A MA50980A (fr) | 2017-07-06 | 2018-07-04 | Application de totarol et composition pharmaceutique contenant du totarol |
MA50979A MA50979B1 (fr) | 2017-07-06 | 2018-07-04 | Application de totarol et composition pharmaceutique contenant du totarol |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA050980A MA50980A (fr) | 2017-07-06 | 2018-07-04 | Application de totarol et composition pharmaceutique contenant du totarol |
Country Status (19)
Country | Link |
---|---|
US (1) | US11534412B2 (fr) |
EP (1) | EP3648751B1 (fr) |
KR (1) | KR20200024921A (fr) |
BR (1) | BR112019027839A2 (fr) |
CA (1) | CA3066602C (fr) |
CL (1) | CL2019003720A1 (fr) |
DK (1) | DK3648751T3 (fr) |
ES (1) | ES2929646T3 (fr) |
HR (1) | HRP20221338T1 (fr) |
HU (1) | HUE060300T2 (fr) |
IL (1) | IL271875B2 (fr) |
LT (1) | LT3648751T (fr) |
MA (2) | MA50980A (fr) |
PL (1) | PL236429B1 (fr) |
PT (1) | PT3648751T (fr) |
RS (1) | RS63728B1 (fr) |
SI (1) | SI3648751T1 (fr) |
UA (1) | UA126031C2 (fr) |
WO (1) | WO2019009739A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114948891A (zh) * | 2021-06-07 | 2022-08-30 | 南通联亚药业股份有限公司 | 药物组合物 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL201869A1 (pl) | 1977-10-29 | 1979-05-21 | Inst Przemyslu Organiczego | Sposob wytwarzania masy kablowej odpornej na dzialanie termitow |
PL107491B1 (pl) | 1977-10-29 | 1980-02-29 | Przemyslowy Instytut Automatyk | Czujnik dwustrunowy do pomiaru malych przesuniec |
JP2700071B2 (ja) | 1988-06-10 | 1998-01-19 | 株式会社資生堂 | 抗菌剤及びそれを用いた皮膚外用剤、口腔用組成物 |
PL166898B1 (pl) | 1992-02-13 | 1995-06-30 | Akad Medyczna | Sposób wytwarzania kompleksu metylocelulozy z kwasem mlekowym |
US6534548B1 (en) * | 2001-10-02 | 2003-03-18 | Kimberly-Clark Worldwide, Inc. | Isoprenoid compositions for the inhibition of exoprotein production from gram positive bacteria |
PL194437B1 (pl) | 2002-06-05 | 2007-05-31 | Akademia Medyczna Im Piastow S | Sposób wytwarzania kompleksu na bazie kwasu mlekowego |
NZ530834A (en) | 2004-01-28 | 2007-06-29 | Owen John Catchpole | Near-critical extraction of totarol and/or a product containing totarol |
US20090312279A1 (en) * | 2005-12-23 | 2009-12-17 | Sterilex Technologies, Llc | Antimicrobial compositions |
EP1925302A1 (fr) * | 2006-11-24 | 2008-05-28 | DSMIP Assets B.V. | Composition diététique où pharmaceutique contentant de diterpène tricycliques et leurs dérivés pour le traitment de la dépression |
EP1925301A1 (fr) * | 2006-11-24 | 2008-05-28 | DSMIP Assets B.V. | Utilisation de diterpènes tricycliques et de leurs dérivés pour le traitement et la prévention d'affections inflammatoires et/ou des articulations |
JP5471335B2 (ja) * | 2009-11-17 | 2014-04-16 | ライオン株式会社 | 口腔バイオフィルム殺菌剤 |
KR20140104011A (ko) * | 2011-12-15 | 2014-08-27 | 콜게이트-파아므올리브캄파니 | 티몰 및 토타롤 항균 조성물 |
WO2014137231A2 (fr) | 2013-03-07 | 2014-09-12 | T2G Biotechnology Limited | Formulations d'extrait de totarol et leurs utilisations |
DE102013108870A1 (de) * | 2013-08-16 | 2015-02-19 | Aimecs Gmbh | Mittel zur Reinigung und zum Schutz von technischen Oberflächen |
CN104027260A (zh) | 2014-06-20 | 2014-09-10 | 广州薇美姿个人护理用品有限公司 | 一种含有桃柘酚的口腔护理用品 |
CN104688810A (zh) | 2014-12-29 | 2015-06-10 | 昆明皕凯科技有限公司 | 一种基于天然植物原料的抗菌组合物及其应用 |
CN106581687A (zh) * | 2016-12-22 | 2017-04-26 | 吉林大学 | 以乳清蛋白为基质的桃柁酚抗菌纳米水凝胶及其制备方法 |
-
2017
- 2017-07-06 PL PL422140A patent/PL236429B1/pl unknown
-
2018
- 2018-07-04 MA MA050980A patent/MA50980A/fr unknown
- 2018-07-04 PT PT187657655T patent/PT3648751T/pt unknown
- 2018-07-04 UA UAA201911771A patent/UA126031C2/uk unknown
- 2018-07-04 ES ES18765765T patent/ES2929646T3/es active Active
- 2018-07-04 SI SI201830794T patent/SI3648751T1/sl unknown
- 2018-07-04 RS RS20221013A patent/RS63728B1/sr unknown
- 2018-07-04 HR HRP20221338TT patent/HRP20221338T1/hr unknown
- 2018-07-04 EP EP18765765.5A patent/EP3648751B1/fr active Active
- 2018-07-04 KR KR1020207003488A patent/KR20200024921A/ko not_active Application Discontinuation
- 2018-07-04 MA MA50979A patent/MA50979B1/fr unknown
- 2018-07-04 CA CA3066602A patent/CA3066602C/fr active Active
- 2018-07-04 US US16/629,005 patent/US11534412B2/en active Active
- 2018-07-04 BR BR112019027839-7A patent/BR112019027839A2/pt unknown
- 2018-07-04 HU HUE18765765A patent/HUE060300T2/hu unknown
- 2018-07-04 DK DK18765765.5T patent/DK3648751T3/da active
- 2018-07-04 LT LTEPPCT/PL2018/000066T patent/LT3648751T/lt unknown
- 2018-07-04 WO PCT/PL2018/000066 patent/WO2019009739A1/fr unknown
-
2019
- 2019-12-18 CL CL2019003720A patent/CL2019003720A1/es unknown
-
2020
- 2020-01-06 IL IL271875A patent/IL271875B2/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2020104832A3 (fr) | 2021-10-08 |
KR20200024921A (ko) | 2020-03-09 |
IL271875A (en) | 2020-02-27 |
PT3648751T (pt) | 2022-10-20 |
SI3648751T1 (sl) | 2023-03-31 |
CL2019003720A1 (es) | 2020-05-22 |
LT3648751T (lt) | 2022-12-12 |
DK3648751T3 (da) | 2022-11-21 |
US11534412B2 (en) | 2022-12-27 |
RS63728B1 (sr) | 2022-12-30 |
HUE060300T2 (hu) | 2023-02-28 |
WO2019009739A4 (fr) | 2019-02-28 |
EP3648751B1 (fr) | 2022-09-28 |
CA3066602A1 (fr) | 2019-01-10 |
HRP20221338T1 (hr) | 2022-12-23 |
UA126031C2 (uk) | 2022-08-03 |
IL271875B (en) | 2022-10-01 |
CA3066602C (fr) | 2024-01-02 |
US20200289429A1 (en) | 2020-09-17 |
IL271875B2 (en) | 2023-02-01 |
RU2020104832A (ru) | 2021-08-06 |
PL422140A1 (pl) | 2019-01-14 |
EP3648751A1 (fr) | 2020-05-13 |
MA50980A (fr) | 2020-10-14 |
MA50979A (fr) | 2020-10-14 |
PL236429B1 (pl) | 2021-01-11 |
WO2019009739A1 (fr) | 2019-01-10 |
ES2929646T3 (es) | 2022-12-01 |
BR112019027839A2 (pt) | 2020-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
MA29378B1 (fr) | Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer | |
MA35070B1 (fr) | Traitements ophtalmiques | |
TN2010000239A1 (fr) | Composition pour l'alimentation humaine et/ou animale ses utilisations, levures | |
MA35422B1 (fr) | Imidazopyridazines amino-substituees | |
US10314914B2 (en) | Iodophor composition and methods of use | |
EP2364692A3 (fr) | Compositions comprenant au moins un derive de l'acide naphtoïque, du peroxyde de benzoyle et au moins un agent filmogene, leurs procedes de preparation, et leurs utilisations | |
FR3065371B1 (fr) | Composition pharmaceutique topique comprenant au moins de l'amitriptyline pour le traitement de douleurs neuropathiques peripheriques | |
CN101222939B (zh) | 眼科用防腐组合物 | |
MA47082B1 (fr) | Amides aromatiques d'acide carboxylique en tant qu'antagonistes des recepteurs bradykinin b1 | |
MA50979B1 (fr) | Application de totarol et composition pharmaceutique contenant du totarol | |
EA202190115A1 (ru) | Пленочные составы, содержащие дексмедетомидин, и способы их получения | |
RU2006131812A (ru) | Фармацевтическая композиция противоспалительного и антимикробного действия в форме мазей на гидрофобной основе для лечения кожных заболеваний (варианты) | |
Boukraâ et al. | Additive action of honey and starch against Candida albicans and Aspergillus niger | |
NO323049B1 (no) | Desinfiseringssammensetning | |
FR2358398A1 (fr) | Medicament a base du sel cereux de la sulfadiazine | |
MA51612A (fr) | Compositions ophtalmiques comprenant de la bilastine, une bêta-cyclodextrine et au moins un agent gélifiant | |
AU765736B2 (en) | Stable xylometazoline and oxymetazoline solution | |
MA57379B1 (fr) | Modulateurs du recepteur alpha associe aux oestrogenes (err-alpha) | |
MA33979B1 (fr) | Piperazines en tant qu'agents antipaludiques | |
MA56608B1 (fr) | Composition et utilisation d'une solution ophtalmique à base d'acide hyaluronique et d'arabinogalactane | |
CN107018999A (zh) | 一种温和稳定的手机杀菌湿纸巾及其应用 | |
US3072525A (en) | Fungicidal composition comprising a salicylate and a pyrazole | |
FR3111817B1 (fr) | Extrait d’Hibiscus sabdariffa et son utilisation pour améliorer la fonction barrière, et favoriser l’hydratation et la desquamation de la peau |